XML 33 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
(Notes)
12 Months Ended
Dec. 31, 2018
Equity [Abstract]  
Shareholders' Equity and Share-based Compensation SHAREHOLDERS’ EQUITY AND SHARE-BASED COMPENSATION

Preferred Stock

The Company's articles of incorporation authorize the issuance of up to 50,000,000 shares of preferred stock, par value $0.01 per share, of which the Company’s Board of Directors has designated 8,000,000 shares of 8.50% Series A Preferred Stock and 7,000,000 shares of 7.625% Series B Preferred Stock, (the Series A Preferred Stock and the Series B Preferred Stock collectively, the “Preferred Stock”). The Company had 2,300,000 shares of its Series A Preferred Stock and 3,654,594 shares of its Series B Preferred Stock issued and outstanding as of December 31, 2018 compared to 2,300,000 shares of Series A Preferred Stock and 3,588,680 shares of Series B Preferred Stock as of December 31, 2017.

The Preferred Stock has no maturity and will remain outstanding indefinitely unless redeemed or otherwise repurchased or converted into common stock pursuant to the terms of the Preferred Stock. The Company's Preferred Stock may be redeemed in whole, or in part, at any time and from time to time at the Company's option at a cash redemption price of $25.00 per share plus any accumulated and unpaid dividends. Because the Preferred Stock is redeemable only at the option of the issuer, it is classified as equity on the Company’s consolidated balance sheet. The Series A Preferred Stock pays a cumulative cash dividend equivalent to 8.50% of the $25.00 liquidation preference per share each year and the Series B Preferred Stock pays a cumulative cash dividend equivalent to 7.625% of the $25.00 liquidation preference per share each year. The Company paid its regular quarterly dividends on its Preferred Stock for the fourth quarter on January 15, 2019 to shareholders of record as of January 1, 2019.
    
Common Stock
    
The Company declared a fourth quarter common stock dividend of $0.18 per share that was paid on January 31, 2019 to shareholders of record as of December 31, 2018.

Stock and Incentive Plans. The Company’s Board adopted the 2018 Stock and Incentive Plan which was approved by the Company’s shareholders on May 15, 2018. The 2018 Plan, which replaced the Company’s 2009 Stock and Incentive Plan (the “2009 Plan”), reserves for issuance up to 3,000,000 shares of common stock for eligible employees, non-employee directors, consultants, and advisors to the Company to be granted in the form of stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance units, and performance cash awards. During the year ended December 31, 2018,
36,924 shares of restricted stock were issued under the 2018 Plan. Awards previously granted under the 2009 Plan will remain outstanding in accordance with their terms, but the Company will not grant any new equity awards under the 2009 Plan.

Total stock-based compensation expense recognized by the Company for the year ended December 31, 2018 was $1,231 compared to $1,954 and $2,709 for the years ended December 31, 2017 and December 31, 2016, respectively. The following table presents a rollforward of the restricted stock activity for the periods indicated:
 
Year Ended
 
December 31,
 
2018
 
2017
 
2016
 
Shares
 
Weighted Average Grant Date Fair Value Per Share
 
Shares
 
Weighted Average Grant Date Fair Value Per Share
 
Shares
 
Weighted Average Grant Date Fair Value Per Share
Restricted stock outstanding as of beginning of period
353,103

 
$
7.01

 
553,396

 
$
7.55

 
696,597

 
$
8.54

Restricted stock granted
213,157

 
6.28

 
138,166

 
6.76

 
214,878

 
6.28

Restricted stock vested
(224,547
)
 
7.28

 
(338,459
)
 
7.80

 
(358,079
)
 
8.71

Restricted stock outstanding as of end of period
341,713

 
$
6.37

 
353,103

 
$
7.01

 
553,396

 
$
7.55



As of December 31, 2018, the grant date fair value of the Company’s remaining nonvested restricted stock is $1,233 which will be amortized into compensation expense over a weighted average period of 1.7 years.